June 17, 2016 | Paratek Pharmaceuticals has stuck with its antibiotic omadacycline over the years, even as three of the company's pharmaceutical partners bailed on the drug. Today the company said that omadacycline hit all its main and secondary goals in a late stage trial. Xconomy